Altamira Therapeutics (CYTO) Stock: Why The Price Surged 55.14%

Apr 12th, 2022 7:08 EST
  • The stock price of Altamira Therapeutics Ltd (NASDAQ: CYTO) increased by 55.14% in the most recent trading session. This is why.

The stock price of Altamira Therapeutics Ltd (NASDAQ: CYTO) increased by 55.14% in the most recent trading session. Investors responded positively to Altamira Therapeutics announcing that the International Journal of Molecular Sciences (IJMS) published a peer-reviewed paper confirming the Company’s positive research findings regarding the in vitro efficacy and safety of its drug-free nasal spray Bentrio against the SARS-CoV-2 Delta variant.

The subject study (conducted by Altamira) tested the safety and efficacy of Bentrio against the Delta variant on an in vitro 3D model of the primary human nasal airway epithelium. And the safety was assessed in assays for tight junction integrity, cytotoxicity, and cilia beating frequency. The study authors concluded: “The results suggest that AM-301 is safe and significantly decelerates SARS-CoV-2 replication in cell culture inhibition assays of prophylaxis (pre-viral load application) and mitigation (post-viral load application). It’s physical (non-pharmaceutical) mechanism of action, safety, and efficacy, warrant additional investigations both in vitro and in vivo for safety and efficacy against a broad spectrum of airborne viruses and allergens.”

Separately, on March 11, the company had announced positive efficacy data from testing its Bentrio nasal spray in vitro against the Omicron variant of SARS-CoV-2.


“We are encouraged by the study reported by IJMS, which demonstrates that Bentrio produced substantial reduction in the viral titer from infection with SARS-CoV-2. With our COVAMID clinical trial, which we initiated in March 2022, we are now testing Bentrio in patients suffering from acute COVID-19. Enrolment has been progressing swiftly so far, and we hope to complete the randomized controlled study during the third quarter.”

“Already in the marketplace in selected European and soon also the first Asian countries, Bentrio offers an affordable, drug-free means of protection against airborne viruses and allergens. We are actively continuing to expand Bentrio’s commercialization footprint — driven by our recently established OTC Consumer Health business unit.”

— Thomas Meyer, Altamira Therapeutics’ founder, Chairman, and CEO

Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.

Link to Source

Leave a Comment

SOTD Membership

Register by Email

Already a member? Sign In